We wish to make a difference for millions of people around the world
About Pharma Equity Group
Our vision
Our vision is to be the biopharmaceutical group that develops the most effective local treatments for serious, acute and chronic inflammatory diseases. Our ambition is to reposition existing drugs to advance drug candidates to a clinical phase III stage. The company’s goal is to seek strategic partnerships that will complete the development of the products and bring them to market, either independently or in collaboration with us.
As a company, it is important to us to be open and make the medical profession comprehensible. We want to be the industry’s most communicative, both when it comes to the role and relevance of the industry and our drug candidates for both patients and society as a whole.
Our mission
Our mission is to assist our subsidiaries in developing new effective medicines for the local treatment of serious, acute, and chronic inflammatory diseases that have significant consequences for patients and society and for which there is currently no optimal treatment.
Our business method and strategy
Pharma Equity Group, listed on the Nasdaq Copenhagen Stock Exchange, strongly emphasizes its portfolio company, Reponex Pharmaceuticals A/S. As a clinical-stage biopharmaceutical company, Reponex Pharmaceuticals is dedicated to developing innovative and effective treatments for diseases that profoundly impact patients and society, especially in cases where current therapies are lacking or require improvement. Pharma Equity Group’s primary focus lies in supporting and nurturing the growth of Reponex Pharmaceuticals within its portfolio. The company actively collaborates with Reponex Pharmaceuticals to help achieve its goals, leveraging the expertise of its experienced professionals in the life science industry, investment, and business development. With a specialized investment focus on early-stage biotechnology companies, Pharma Equity Group recognizes the potential of Reponex Pharmaceuticals’ novel therapies for unmet medical needs.
By maintaining Reponex Pharmaceuticals within its portfolio, Pharma Equity Group ensures a dedicated and strategic approach to driving its success.
Furthermore, Pharma Equity Group’s network of industry partners and advisors strengthens its commitment to Reponex Pharmaceuticals’ growth and development. The company’s overall strategy emphasizes creating a cost-efficient and flexible environment, enabling rapid mobilization of relevant resources—a key factor that drives the success of Reponex Pharmaceuticals’ innovative initiatives.
Our history
Pharma Equity Group has a history rooted in strategic investments within the pharmaceutical and healthcare industries. Established with a mission to drive innovation and value, the company has focused on acquiring and developing promising ventures across the sector. A significant part of its portfolio includes Reponex Pharmaceuticals, a key player in developing advanced therapeutic solutions based on the repositioning of known drugs.
Global patents
Since the early beginning of Reponex Pharmaceuticals in 2011, we have developed 6 drug candidates. In our development process we have always kept our generic repositioning approach in mind. All of our drug candidates hold the purpose of addressing diseases, where there is currently no or little pharmaceutical help
